Nimenrix NHS

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W135, and Y.1

Invasive Meningococcal Disease (IMD) is primarily associated with meningitis and septicaemia which can be fatal or have long-term survival consequences, even with appropriate medical care.2,3  



Age and social mixing behaviours can put a person at greater risk for contracting invasive meningococcal disease.5
        Adolescents and young adults have the highest asymptomatic carriage rates, with almost 25% of 19-year-olds carrying the bacteria at
          any one time.6,7  
        Social behaviours associated with an increased risk of invasive meningococcal disease in adolescents and young adults include:3,5,6,13


Nimenrix is recommended on the routine immunisation schedule and is offered to teenagers aged 13-15 years old in school years 9 and 10.8,9
Some young adults today may not have received a MenACWY vaccination. 

If your patients were born on or after 1 September 1996 and are eligible but missed their teenage MenACWY vaccine, they can still have the vaccine up to their 25th birthday. If they are starting university for the first time, they can still have the vaccine up to their 25th birthday.9,10

These 3 simple steps can help protect your patients who are still eligible to receive a MenACWY vaccine:


Nimenrix is also recommended for patients with specific medical conditions, these include those with:8

       asplenia or splenic dysfunction (including due to sickle cell and coeliac disease)
       complement disorders (including those receiving complement inhibitor therapy)

Please visit chapter 22 of the Green book for more information.

Nimenrix Supply
For the routine immunisation programme Nimenrix should be ordered via the IMMFORM website

For more information
Contact our Pfizer Vaccines team on: 0800 089 4033 or email [email protected]


  1. Nimenrix. Summary of Product Characteristics, United Kingdom: Pfizer Ltd. Available here
  2. Vyse A, Anonychuk A, Jakel A, et al. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597–604.
  3. World Health Organization. Meningococcal meningitis, fact sheet. Available at: (last accessed June 2020).
  4. Chang Q, Tzeng Y, Stephens D. Meningococcal disease: changes in epidemiology and prevention. Clinical Epidemiology. 2012;4 237–245.
  5. Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59 (2 suppl):S12–S20.
  6. Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission and disease. Expert Rev Vaccines 2016;15(5):641–58.
  7. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61.
  8. Public Health England. Complete routine immunisation schedule. Available at: (last accessed June 2020).
  9. NHS. Vaccinations: MenACWY Vaccines. Available at: (last accessed June 2020).
  10. Public Health England. Vaccine Update, Issue 293, April 2019. Available at: (last accessed June 2020).
  11. Public Health England. Vaccination of individuals with uncertain or incomplete immunisation status. Available at: (last accessed June 2020).
  12. European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Available at: (last accessed June 2020).
  13. Muttalif A, Presa, J, Haridy, H et al. Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events. Infect Dis Ther. 2019;8:569–579.

Prescribing Information
Nimenrix™ prescribing information.


PP-NIM-GBR-0220.  June 2020